Greenphire launches reimbursement solutions for decentralized trials

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/cristalov)
(Image: Getty/cristalov)

Related tags: Greenphire, Clinical trials, Patient centricity, patient engagement

The company’s ClinCard patient payment offering now includes data-triggered capabilities and direct-to-patient debit card delivery.

Sites and sponsors are finding COVID-19 is having significant impact on their clinical research, particularly in the area of patient engagement. In a move designed to help trial teams increase patient convenience, Greenphire has added data-triggered payment functions and debit card delivery right to patients as part of its its ClinCard reimbursement solution.

According to Greenphire chief product officer Kyle Cunningham, the disruptions caused by the pandemic are creating an increased need for decentralized payment functions

"As the landscape for clinical trials evolves, we're beginning to see a need for remote payment capabilities. We heard from over 1,800 site personnel and over 80% said that providing a small payment following a virtual visit would improve the likelihood of participants staying in a clinical trial​," he said.

It's of utmost importance to keep clinical trials running in this uncertain time. As a company dedicated to removing barriers to both sites and patients, we're thrilled to offer these new capabilities for our ClinCard solution so that patients can stay engaged and enrolled in trials and sites can continue their critical work​," Cunningham added.

Zach Hales, Greenphire product manager, said while decentralized trials and technology supporting remote research has been evolving in recent years, COVID-19 has pushed the industry to accelerate in that direction.

"Virtual or hybrid clinical trials have been talked about for some time, but today's pandemic has brought the digital trial format from a slowly emerging concept to an approach that can provide essential utility for patients and sites alike – especially during difficult times as we're experiencing today. Understanding this need, we advanced our product roadmap to help patients stay active in trials and enable sites to continue to collect vital data,​" Hales said.

With the data-triggered payment function, users can process payments in their office or remotely. The technology’s open-API design enables users to integrate with any data supporting event-driven scenarios, such as electronic data capture, clinical trial management software, clinical outcome assessments and more.

According to Greenphire, enabling remote reimbursement can help improve patient engagement, compliance and retention. The function is designed to enable users to complete payment in real time for pre-determined event schedules, without increasing administrative burdens at sites.

Additionally, ClinCard now enables sites to send debit cards directly to participant homes. It also allows expense reimbursement tracking, including notes for virtual receipts, to help streamline reimbursement.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more